Letter (brief communication): A pilot study of hemp hull bio gut fibre (BGF) to reduce intestinal permeability in IBS ‐ BAD
Alimentary Pharmacology & Therapeutics · 2024
DOI: 10.1111/apt.18164 ↗At a glance
Leserbrief in Alimentary Pharmacology & Therapeutics, 2024. Written by Camille Lupianez-Merly and 7 co-authors. Institution: Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rocheste…. Major MEDLINE topics: Dietary Fiber, Intestinal Barrier Function, Irritable Bowel Syndrome. Cited 1 times so far (Crossref); 10 references. Funded by: NIDDK NIH HHS.
Abstract (original language)
Intestinal barrier (IB) dysfunction plays a role in pathogenesis of intestinal diseases including irritable bowel syndrome (IBS) with bile acid diarrhoea (BAD). 1 Dietary nutrients or supplements including whole grains may enhance IB functions by restoring the gut micro-biome, mucus layer thickness, 2 and effects on tryptophan and short chain fatty acids (SCFA). 3,4 Hemp seeds provide all essential amino acids, polyunsaturated fats, fibre, minerals and vitamins. 5 Hemp hulls are also rich in bioactive phenolics, which enhance gut barrier function in vitro. 6 Bio gut fibre (BGF) is a minimally processed fibre ingredient from hemp hulls and is generally recognized as safe (GRAS status, U.S. FDA 2021a). We hypothesized that BGF reduces intestinal permeability in BAD. In a pilot, single-arm, open-label, prospective study, 10 participants with a prior biochemical diagnosis of BAD (based on serum [ n = 8] or stool [ n = 2]) associated with IBS consumed 10 g BGF twice daily for 3 weeks, delivering 15 g of insoluble dietary fibre. At base - line and end of treatment, they underwent measurements of small intestinal (SI) and colonic permeability (IP) 7 using oral 100 mg 13 C-mannitol (estimated molecular diameter [EMD] 6.7 Å) and 1 g lac - tulose (EMD 9.5 Å), based on sugars' excretion at 0–2 h (reflecting upper small bowel), 2–8 h (SI and proximal colon) and 0–24 h (total
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
- Brightseed, South San Francisco, California, USA.
ORCID profiles: Michael Camilleri
Funding
- NIDDK NIH HHS
Cite
APA
Lupianez-Merly, C., Jencks, K., Dilmaghani, S., Ferber, M., Melo, L., van Klinken, B. J., Kalgaonkar, S., & Camilleri, M. (2024). Letter (brief communication): A pilot study of hemp hull bio gut fibre (BGF) to reduce intestinal permeability in IBS ‐ BAD. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18164
Vancouver
Lupianez-Merly C, Jencks K, Dilmaghani S, Ferber M, Melo L, van Klinken BJ, et al. Letter (brief communication): A pilot study of hemp hull bio gut fibre (BGF) to reduce intestinal permeability in IBS ‐ BAD. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18164
BibTeX
@article{LupianezMerly2024,
author = {Lupianez-Merly, Camille and Jencks, Kara and Dilmaghani, Saam and Ferber, Monique and Melo, Luma and van Klinken, B Jan-Willem and Kalgaonkar, Swati and Camilleri, Michael},
title = {Letter (brief communication): A pilot study of hemp hull bio gut fibre (BGF) to reduce intestinal permeability in IBS ‐ BAD},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
doi = {10.1111/apt.18164}
}
EUVIMED